Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “AstraZeneca”

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainRecruiting
NCT07029737Phase 2Updated Aug 3, 2026
Sponsor: AstraZeneca
Mantle-cell Lymphoma
Spain
Study for AZD4360 in Participants With Advanced Solid TumoursActive Not Recruiting
NCT06921928Phase 1, Phase 2Updated Jul 31, 2026
Sponsor: AstraZeneca
Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract Cancer · Pancreatic Ductal Adenocarcinoma
United States, China, Germany, Japan, United Kingdom
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With DapagliflozinRecruiting
NCT06677060Phase 3Updated Jul 31, 2026
Sponsor: AstraZeneca
Heart Failure
United States, Argentina, Australia, Brazil, Bulgaria +30 more
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of AZD3974 in Healthy ParticipantsRecruiting
NCT07290283Phase 1Updated Jul 31, 2026
Sponsor: AstraZeneca
Healthy Participants
United States
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus NephritisActive Not Recruiting
NCT05138133Phase 3Updated Jul 31, 2026
Sponsor: AstraZeneca
Lupus Nephritis
United States, Argentina, Belgium, Brazil, Bulgaria +19 more
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive Not Recruiting
NCT02446600Phase 3Updated Jul 31, 2026
Sponsor: National Cancer Institute (NCI)
Fallopian Tube Clear Cell Adenocarcinoma · Fallopian Tube Transitional Cell Carcinoma · Fallopian Tube Undifferentiated Carcinoma · Ovarian Clear Cell Adenocarcinoma
United States, Canada, Japan, South Korea
Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)Active Not Recruiting
NCT04656652Phase 3Updated Jul 31, 2026
Sponsor: Daiichi Sankyo
Non-small Cell Lung Cancer
United States, Argentina, Australia, Belgium, Brazil +21 more
A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLCActive Not Recruiting
NCT04606771Phase 2Updated Jul 30, 2026
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
United States, Argentina, India, Taiwan, Thailand +1 more
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)Active Not Recruiting
NCT04784715Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Breast Cancer; HER2-positive; Metastatic
United States, Argentina, Belgium, Brazil, Canada +22 more
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).Not Yet Recruiting
NCT07735637Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Newly Diagnosed Multiple Myeloma (NDMM)
United States, Australia, Brazil, Canada, Denmark +10 more
Efficacy and Safety of Tezepelumab in Patients With Eosinophilic EsophagitisActive Not Recruiting
NCT05583227Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Eosinophilic Esophagitis
United States, Australia, Austria, Belgium, Brazil +17 more
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruiting
NCT06380751Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Advanced Breast Cancer
United States, Argentina, Australia, Austria, Brazil +24 more
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GlioblastomaRecruiting
NCT03970447Phase 2, Phase 3Updated Jul 30, 2026
Sponsor: Global Coalition for Adaptive Research
Glioblastoma
United States, Australia, Canada, France, Germany +1 more
Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology AgentsRecruiting
NCT06963346Phase 1Updated Jul 30, 2026
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Bladder Cancer
United States
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of SaruparibActive Not Recruiting
NCT06899061Phase 1Updated Jul 30, 2026
Sponsor: AstraZeneca
Advanced Solid Malignancies
Bulgaria, Moldova, Romania
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.Recruiting
NCT07215702Phase 2Updated Jul 30, 2026
Sponsor: AstraZeneca
Sepsis · Acute Kidney Injury
United States, Argentina, Belgium, Canada, Czechia +9 more
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant HypertensionCompleted
NCT06034743Phase 3Updated Jul 30, 2026
Sponsor: AstraZeneca
Uncontrolled Hypertension · Resistant Hypertension
United States, Argentina, Australia, Austria, Belgium +24 more
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced FibrosisRecruiting
NCT07610837Phase 2Updated Jul 29, 2026
Sponsor: AstraZeneca
Liver Fibrosis · Hepatic Cirrhosis
United States
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsRecruiting
NCT07201558Phase 1Updated Jul 29, 2026
Sponsor: AstraZeneca
Rheumatoid Arthritis · Systemic Lupus Erythematosus
United States, Australia, Belgium, Brazil, China +5 more
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)Recruiting
NCT07044336Phase 3Updated Jul 29, 2026
Sponsor: AstraZeneca
Endometrial Cancer · Malignant Solid Tumour
United States, Argentina, Australia, Austria, Belgium +23 more
Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST CancerRecruiting
NCT07070128N/AUpdated Jul 29, 2026
Sponsor: AstraZeneca
Breast Neoplasms
Brazil
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal AgentsActive Not Recruiting
NCT06120491Phase 3Updated Jul 29, 2026
Sponsor: AstraZeneca
Metastatic Castration-Sensitive Prostate Cancer
United States, Australia, Austria, Belgium, Brazil +19 more
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2Recruiting
NCT06219941Phase 2Updated Jul 29, 2026
Sponsor: AstraZeneca
Gastric Cancer · Gastroesophageal Junction Cancer · Biliary Tract Cancer · Pancreatic Ductal Adenocarcinoma
United States, Australia, Canada, China, Georgia +9 more
Rash & Diarrhea Prophylaxis With CapivasertibRecruiting
NCT07426822Phase 2Updated Jul 29, 2026
Sponsor: Maryam Lustberg
Metastatic HR+/HER2- Breast Cancer
United States
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus ErythematosusActive Not Recruiting
NCT06015737Phase 3Updated Jul 29, 2026
Sponsor: AstraZeneca
Cutaneous Lupus Erythematosus
United States, Argentina, Australia, Austria, Brazil +27 more

Previous page Next page